• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Arvinas Inc (NQ: ARVN )

    26.81 +0.63 (+2.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 396,553
    Open 26.41
    Bid (Size) 25.67 (1)
    Ask (Size) 28.80 (1)
    Prev. Close 26.18
    Today's Range 25.82 - 27.12
    52wk Range 13.57 - 53.08
    Shares Outstanding 68,600,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Latest Analyst Ratings For Arvinas
    Via Benzinga
    ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
    ARVN stock results show that Arvinas beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -35.40%
    -35.40%
    1 Month
    -3.49%
    -3.49%
    3 Month
    -23.94%
    -23.94%
    6 Month
    -45.05%
    -45.05%
    1 Year
    +0.87%
    +0.87%

    More News

    Read More
    Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Analyst Ratings For Arvinas
    Via Benzinga
    Biotech Arvinas Stock Earns 82 RS Rating
    Via Investor's Business Daily
    Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
    From Arvinas Inc.
    Via GlobeNewswire
    These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
    Via Talk Markets
    Arvinas to Participate in Upcoming Investor Conferences
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
    From Arvinas Inc.
    Via GlobeNewswire
    Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
    From Arvinas Inc.
    Via GlobeNewswire
    NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
    From Arvinas Inc.
    Via GlobeNewswire
    ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas to Present at Upcoming Investor Conferences
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
    From Arvinas Inc.
    Via GlobeNewswire
    Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
    Via Investor's Business Daily
    Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
    From Arvinas Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.